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Abstract
Background. Cross-sectional studies show that the prevalence of comorbid depression in
people with tuberculosis (TB) is high. The hypothesis that TB may lead to depression has
not been well studied. Our objectives were to determine the incidence and predictors of prob-
able depression in a prospective cohort of people with TB in primary care settings in Ethiopia.
Methods. We assessed 648 people with newly diagnosed TB for probable depression using
Patient Health Questionnaire, nine-item (PHQ-9) at the time of starting their anti-TB medi-
cation. We defined PHQ-9 scores 10 and above as probable depression. Participants without
baseline probable depression were assessed at 2 and 6 months to measure incidence of
depression. Incidence rates per 1000-person months were calculated. Predictors of incident
depression were identified using Poisson regression.
Results. Two hundred and ninety-nine (46.1%) of the participants did not have probable
depression at baseline. Twenty-two (7.4%) and 26 (8.7%) developed depression at 2 and 6
months of follow up. The incidence rate of depression between baseline and 2 months was
73.6 (95% CI 42.8–104.3) and between baseline and 6 months was 24.2 (95% CI 14.9–33.5)
per 1000 person-months respectively. Female sex (adjusted β = 0.22; 95% CI 0.16–0.27) was
a risk factor and perceived social support (adjusted β =−0.14; 95% CI −0.24 to −0.03) was
a protective factor for depression onset.
Conclusion. There was high incidence of probable depression in people undergoing treatment
for newly diagnosed TB. The persistence and incidence of depression beyond 6 months need
to be studied. TB treatment guidelines should have mental health component.
Introduction
Cross-sectional studies in both high income (Trenton and Currier, 2001) and low and middle
income countries (Mathai et al., 1981; Aydin and Ulusahin, 2001; Moussas et al., 2008; Issa
et al., 2009; Sulehri et al., 2010; Ige and Lasebikan, 2011; Panchal, 2011; Doherty et al.,
2013; Duko et al., 2015) show that comorbid depression among people with TB is a common
debilitating condition with a prevalence of as high as 50.0% (Sweetland et al., 2018). Recently,
we have analyzed the prevalence of probable depression in people newly diagnosed with tuber-
culosis (TB) at the time of initiation of their anti-TB medication in primary care settings in
Ethiopia and found that it was 54.0% on nine-item version of Patient Health Questionnaire
(PHQ-9) at a cut-off point of 10 and above (Ambaw et al., 2017).
Attempts to understand the type of relationship between TB and depression are limited. A
number of explanations have been given in the literature (Sweetland et al., 2017). Some evi-
dence suggests that TB and depression may share risk factors (Kiecolt-Glaser and Glaser,
2002; Reiche et al., 2004; Katon et al., 2007). Others explain that TB can be contracted as a
result of compromised immunity and neglected self-care associated with depression (Reiche
et al., 2004). Such evidence shows that depression enhances the production of proinflamma-
tory cytokines and directly minimizes immunological competence by down regulating cellular
and humoral responses (Kiecolt-Glaser and Glaser, 2002; Reiche et al., 2004; Katon et al., 2007;
Katon, 2011). The third hypothesis, which is also the focus of this study, is that people with TB
may develop depression through various mechanisms including chronic infection and related
disability and psycho-socioeconomic stressors (Mikkelsen et al., 2004), effects of TB medica-
tions such as isoniazid (Madan et al., 1989), chronic infectious conditions which may lead to
overproduction of proinflammatory cytokines such as interleukin 6, which facilitate cascades
of endocrine reactions that are suggested to result in depressive symptoms (Kiecolt-Glaser and
Glaser, 2002), and general physical and psychological losses (Mikkelsen et al., 2004; Pachi
et al., 2013). However, whether people with a newly diagnosed TB receiving anti-TB
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medications will develop new depressive disorder or not has not
been properly studied. A study in Taiwan followed people with
TB for a mean period of 6.5 years and reported that they had a
higher incidence of depression compared to controls. This study
has not adequately controlled socioeconomic factors and has
included only cases of pulmonary TB (Yen et al., 2015).
Understanding whether incident depression occurs in people
with TB after starting anti-TB care is critically required to
improve the national guideline for clinical and programmatic
management of TB in Ethiopia and similar settings that lack men-
tal health component (Federal Ministry of Health of Ethiopia,
April 2012), and to target depression interventions in the integra-
tion of mental health care into primary care which is being scaled
up in Ethiopia (FMOH, 2012a, 2012b). It also provides a strong
base to conduct well designed studies on the relationship between
depression and anti-TB medications, specifically isoniazid
(Doherty et al., 2013) and ethambutol (Yen et al., 2015),
TB-related stigma or behavioral factors specific to this population
(Sweetland et al., 2018).
The objectives of this study were to assess incidence rates of
probable depression at 2 and 6 months after starting anti-TB
treatment and to identify factors predicting incidence in the con-
text of TB and its treatment.
Methods
Design
This study was part of a 6 month prospective observational cohort
that examined the interaction between depression and newly diag-
nosed TB in primary care settings in Ethiopia (Ambaw et al.,
2015). At the time of diagnosis and treatment initiation for TB,
we assessed for depression and we classified participants into
‘having probable depression’ and ‘not having probable depression’
based on PHQ-9, scores. We then followed those ‘not having
probable depression’ for incidence of probable depression during
the 6 month follow up period.
Study setting
The study was conducted from December 2014 to July 2016 in 14
primary care centers located in south central (i.e. in Silti and
Gurage zones) and northern (i.e. Bahir Dar zone) Ethiopia.
Two of the primary care centers were hospitals and 12 were health
centers. Similar services were provided at the health centers and
hospitals: providers of TB care were nurses or public health offi-
cers that have taken the same trainings on TB care, the same med-
ications were given at both institutions, and the same treatment
guidelines were used. All people with newly diagnosed TB in
the outpatient departments were being treated according to the
Directly Observed Treatment, Short course (DOTS) regimen.
DOTS has 6 months duration with intensive and continuation
phases. The intensive phase consists of treatment with combin-
ation of four medications (rifampicin, ethambutol, isoniazid,
and pyrazinamide) for the first 2 months, and the continuation
phase consists of a combination of two medications (rifampicin
and isoniazid), to be taken for 4 months immediately after the
intensive phase (Federal Ministry of Health of Ethiopia, April
2012).
The frontline nurses and public health officers working in
those primary care centers received training in the management
of mental disorders according to the evidence-based WHO
Mental health Gap Action Programme Intervention Guide
(mhGAP-IG) for mental, neurological, and substance use disor-
ders in non-specialized health care settings (WHO, 2016). The
presence of staff that took this training and TB patient flow of
at least five per month were criteria to include the primary care
centers in the study areas.
Eligibility criteria
– People attending the selected health centers for TB treatment
who were within 1 month of starting anti-TB treatment
– Aged 18 years and above
– No plan to move out of the study area
– Not too ill to be interviewed at baseline as perceived by the
interviewer or the prospective participant
– Had not been admitted to an in-patient unit for more than 5
days in the last 1 month as the additional stressors of being
hospitalized represent a different range of risk factors for
depression.
– Not diagnosed with Multidrug-Resistant Tuberculosis (MDR-
TB); people with MDR-TB constitute a different population
because their treatment and outcomes are different (medications
with a higher side effect burden and taken for a much longer
duration; poorer prognosis) and MDR-TB is amore feared and
stigmatized condition (Vega et al., 2004). Furthermore, only
one of the study health facilities had recently started a service
for people with MDR-TB.
– Not on re-treatment for TB as people who experienced previous
treatment failures are at high risk of MDR-TB and constitute a
different risk group for depression.
Sample size
The total sample size was 648. The sample size was based on the
primary objective of the planned longitudinal study which was to
examine the effect of depression on default from anti-TB treat-
ment (Ambaw et al., 2015) and was calculated using the following
parameters: 80% power, 95% confidence level, 2.5% prevalence of
treatment default among patients with TB and without depres-
sion, 7.5% prevalence of treatment default among people with
TB and co-morbid depression and a ratio of 2:1 of non-exposed
(not depressed) to exposed (depressed) participants. This pro-
vided a required sample size of 639. With a contingency of 10%
for possible loss to follow up, the target sample was 703 people
with TB.
Variables and measurements
Dependent variable: probable depression
Depression was measured using the PHQ-9. The PHQ-9 assesses
the presence of nine depressive symptoms over the past 2 weeks in
an individual; the possible responses are: not at all (0), several
days (1), more than half of the days (2) and almost every day
(3); possible composite score ranges from zero to 27. Globally,
the scale is widely used in surveys, effectiveness trials and cohort
studies in various populations (Kroenke et al., 2010). In Ethiopia,
it has been validated two times and was found to be useful in
screening depression in adult out patients (Gelaye et al., 2013;
Hanlon et al., 2015). The optimum cut-off point was five and
above in primary healthcare centers in a rural district (Hanlon
et al., 2015) and 10 and above in outpatient medical clinics in a
referral hospital in Addis Ababa (Gelaye et al., 2013). We applied
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the more conservative cut-off point of 10 and above to define
probable depression. In the baseline data of this study, the
PHQ-9 had a single dimension structure, a Cronbach’s α value
of 0.81 and a mean inter-item correlation coefficient of 0.33
(Ambaw et al., 2017). In this manuscript, the term depression is
used instead of probable depression for simplicity purpose.
Independent variables
(I) Socio-demographic variables: age, sex, marital status, level of
education, religion, household income, occupation and place
of residence (urban v. rural) were measured by self-report.
Household income was measured by asking the participants
to estimate the monthly total income of their household.
When the participant was a farmer, we changed the esti-
mates of annual income in kind to cash using the local mar-
ket price. We converted the monthly income into annual
income.
(II) Perceived social support: perceived social support was mea-
sured using the three-Item Oslo Scale of Perceived Social
Support (OSLO-3) with scores ranging from 3–14
(Meltzer, 2003). The scale was previously reported to work
well in TB patients in Ethiopia (Duko et al., 2015). In this
sample the scale had an α value of 0.61 and a mean inter-
item correlation of 0.35. Higher scores on OSLO-3 show
better perceived social support.
(III) TB-related stigma: TB related stigma was measured at the
second assessment using a 10-item TB stigma scale adapted
from Macq and colleagues (Macq et al., 2006), translated
into Amharic, and piloted (Ambaw et al., 2015). In this
sample, the scale had an α value of 0.84 and a mean inter-
item correlation coefficient of 0.34. Higher scores on the
TB-related stigma scale show a higher level of stigma.
(IV) Substance use: alcohol, tobacco, and khat use were measured
using the WHO Alcohol, Smoking and Substance
Involvement Screening Test (ASSIST) (version 3.1)
(WHO, 2010). The ASSIST was designed for use across dif-
ferent cultural settings. The instrument’s psychometric
properties have been tested using data from multiple coun-
tries, including low, middle, and high income countries and
shown to be valid, reliable, and easy to administer across set-
tings (Humeniuk et al., 2008). The ASSIST risk score ranges
from 0–31 for tobacco and 0–39 for alcohol and khat. The
risk score of the respondents obtained for alcohol is categor-
ized into ‘low’ (0 to 10), ‘moderate’ (11 to 26) or ‘high’ risk
(above 26), and for khat low (0 to 3), moderate (4 to 26),
and high (above 26) (WHO, 2010).
(V) Comorbid illness: data on the presence of chronic illnesses
other than TB were obtained by asking the question ‘Have
you ever been told by health professionals to have cardiac
illness, hypertension, diabetes mellitus, depression, or men-
tal illnesses other than depression?’ HIV status was recorded
from the TB register after informed consent.
(VI) Type of TB: It refers to whether the TB was pulmonary or
extra-pulmonary. It was captured from the TB register in
the health facilities using a structured checklist.
Recruitment and ethics
People with newly diagnosed TB who fulfilled the inclusion cri-
teria were identified, informed, and invited to participate in the
study by health professionals running TB clinics at the health
facilities. When the individuals expressed interest to participate,
they were linked to trained nurse research assistants who provided
them detail information, sought written informed consent or wit-
nessed thumb print, and carried out the data collection generally
at the health facilities. The information provided to participants
was explained face-to-face and delivered in written form to parti-
cipants. The proposal was approved by the Institutional Review
Board of College of Health Sciences of Addis Ababa University
(number 027/14/Psy) before data collection. In the process of
data collection, respondents who endorsed the suicide item of
PHQ-9 were referred to health workers within the health facilities
for further evaluation and treatment.
Follow up
The first (Baseline) assessment was done at the time of starting
the medications. The second (2 months): assessment was done
after participants took anti-TB medication for 2 months. The
third (6 month) assessment was done after participants took the
full course of their anti-TB medication. Figure 1 details the flow
of participants at each assessment time.
Ascertainment of time to follow up
Time of loss to follow-up was taken as midway between the last
successful attempt to contact and the first unsuccessful attempt
to contact, following the convention when exact times are not
captured (Rothman et al., 2008). Participants assessed at baseline
but unavailable for measurements at 2 months were defined as
contributing one person-month. Participants assessed at 2
months but unavailable at 6 months were defined as contributing
four person-months. Participants followed for the whole 6
months had six person-months.
Data analysis
Data were analyzed using STATA version 15 (StataCorp. URL:
http://www.stata.com). Descriptive statistics were used to sum-
marize the data and to calculate incidence rates of depression.
Poisson regression was used to identify predictors of incidence
and findings were presented using adjusted β (beta) coefficients
(Lumley and Kronmal, 2006). Robust and cluster standard errors
were used as the study institutions were located in the southern
and northern regions of the country. The inclusion of independ-
ent variables in the multivariable analysis was based on its theor-
etical importance and adequacy of the number of participants in
cells for each category (Tabachnic and Fidell, 2007). Regression
analysis included participants with more than one assessment
for depression. Statistical significance was set at p value less
than 0.05. The Strengthening the Reporting of Observational
Studies in Epidemiology guidelines have been used to report
our findings (von Elm et al., 2007).
Results
Characteristics of participants
A total of 648 participants were assessed at baseline for depres-
sion. Sixty two (9.6%) transferred out of the study area after
being recruited into the study. Participants were in the age
range of 18–85 years with a median of 30 years. Just over half
(n = 348; 53.7%) were male, 224 (34.6%) had no formal education,
and 172 (26.5%) were farmers. The average annual household
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income was 659.0 USD (standard deviation = 697.0) (Table 1).
Seventy four participants (11.4%) were living with HIV. Five,
three, and one participant had diabetes, cardiac illness, and
hypertension respectively. No participant reported to have a pre-
viously diagnosed depression. Twelve (1.9%), eleven (1.7%), and
four (0.6%) had high risk alcohol, khat, and tobacco use respect-
ively (Table 2).
Incidence rate of depression
Two hundred ninety nine participants without baseline depres-
sion were followed for a total of 299 and 1076 person-months
at the 2nd month and the end of the follow up respectively.
Two hundred seventy nine participants had more than one assess-
ment for depression. The median duration between starting
ant-TB medication and the first (baseline) assessment was zero
days with a mean of 1.6 days and a standard deviation of
3.5 days. The second (2 months) assessment was done after
participants took anti-TB medication for a median duration of
56.0 days with a mean of 57.0 days and a standard deviation of
3.0 days. The third (6 month) assessment was done after partici-
pants took their anti-TB medication for a median duration of
160 days with a mean of 162 days and a standard deviation of
4.8 days.
Among the 299 participants who did not have probable
depression at baseline, 22 (7.4%) developed within the first
2 months of follows up; other four participants developed prob-
able depression in the next 4 months making the total number
of new cases 26 (8.7%) (Fig. 2). The incidence rates of depression
at 2 and 6 months were 73.6 (95% CI 42.8–104.3) and 24.2 (95%
CI 14.9–33.5) per 1000 person-months, respectively. At 2 months,
being female (adjusted β = 0.40; 95% CI 0.16–0.63), married
(adjusted β = 0.37; 95% CI 0.34–0.40), and having pulmonary
TB v. extra-pulmonary TB (adjusted β = 0.23; 95% CI 0.001–
0.45) independently predicted incidence. Higher perceived social
support was found to be protective against depression onset
(adjusted β =−0.15; 95% CI −0.23 to −0.07). At 6 months,
these variables were still independent predictors of incidence
except marital status (adjusted β = 0.04; 95% CI −0.001 to 0.08)
(Table 3).
Fig. 1. Flow chart of participants of the study.
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Discussion
A high incidence rate of probable depression was found in people
with newly diagnosed TB undergoing treatment using the DOTS
regimen. In a previous manuscript we found that depression was
associated with increased mortality and treatment default rates in
people with TB (Ambaw et al., 2018). In general, depression
co-occurring with physical conditions decreases treatment adher-
ence (Katon, 2011) and substantially increases mortality (Wulsin
et al., 1999). Taking the harm comorbid depression in people with
TB can cause (Sweetland et al., 2017; Ambaw et al., 2018), and the
fact that the incident cases occurred in people who were under the
attention of healthcare providers into consideration, the incidence
rate observed in our study can be interpreted as alarmingly high.
In fact, the incidence rate we found is higher than what was
reported for people living with HIV both in Uganda, Africa
(Kinyanda et al., 2016) and France, Europe (Nacher et al., 2010;
Elenga et al., 2014), type-2 diabetic patients (Lunghi et al.,
2016), or nursing homes (Boorsma et al., 2012). Previous
researchers also reported that depression is more prevalent in
people with TB than with other physical illnesses (Doherty
et al., 2013). The global incidence rate of unipolar depression
Table 1. Socio-demographic characteristics of participants (n = 648)
Variable Number (%)/mean; range
Sex
Male 348 (53.7)
Female 300 (46.30)
Age in years 34.4 ± 14.6; 18–85
Marital status
Single 210 (32.4)
Married 358 (55.3)
Widowed or divorced 80 (12.4)
Level of education
No formal education 224 (34.6)
Primary education 260 (40.1)
Secondary or above 164 (25.3)
Occupation
Unemployed 37 (5.7)
Government employee 61 (9.4)
Self-employed 133 (20.5)
Farmer 172 (26.5)
Student 39 (6.0)
Housewife 111 (17.1)
Daily laborer 44 (6.8)
Other 51 (7.9)
Annual household income in USD 659.0 ± 697.0; 24.0–5940.0
Religion
Christian 429 (66.2)
Muslim 219 (33.8)
Residence
Urban 364 (56.2)
Rural 284 (43.8)
Ethnicity
Amhara 306 (47.2)
Gurage 192 (29.6)
Mareko 68 (10.5)
Silte 65 (10.0)
Oromo 11 (1.7)
Other 6 (0.9)
Perceived social support (Oslo-3
score)
9.8 ± 2.5; 3–14
TB stigma score 27.0 ± 7.6; 10–48
Table 2. Illness and substance use in the participants (N = 648)
Variables Number (%)
Type of TB
Pulmonary 371 (57.3)
Extra pulmonary 277 (42.8)
HIV status
Negative 495 (76.4)
Positive 74 (11.4)
Unknown 79 (12.2)
Hyper tension
No 647 (99.8)
Yes 1 (0.2)
Cardiac illness
No 645 (99.5)
Yes 3 (0.5)
Diabetes mellitus
No 643 (99.2)
Yes 5 (0.8)
Prior depression
No 648 (100)
Yes 0
Level of alcohol risk:
Low 562 (86.7)
Moderate 74 (11.4)
High 12 (1.9)
Level of tobacco risk
Low 615 (94.9)
Moderate 29 (4.5)
High 4 (0.6)
Level of khat risk
Low 544 (84.0)
Moderate 93 (14.3)
High 11 (1.7)
Global Mental Health 5
https://www.cambridge.org/core/terms. https://doi.org/10.1017/gmh.2019.27
Downloaded from https://www.cambridge.org/core. IP address: 196.190.127.228, on 03 Jan 2020 at 10:47:20, subject to the Cambridge Core terms of use, available at
was estimated to be 49/100000/year for women and 31/100000/
year for men in 2000 (Ustun et al., 2004), incomparably lower
than that observed in TB suggesting that TB care guidelines
should include mental health components. Sweetland and collea-
gues (Sweetland et al., 2018) have proposed that TB care is an
appropriate component of the existing health services to integrate
mental health in primary care in low-resource settings.
Higher incidence of depression in people with TB compared to
the general population had been reported in Taiwan (Shen et al.,
2014, Yen et al., 2015). The incidence rate observed in our study
was substantially higher than that reported in Taiwan probably
because studies in Taiwan followed people with TB for about 12
years including mainly TB-free period of the participants (Shen
et al., 2014; Yen et al., 2015). Shen et al. (2014) found the highest
number of incident cases during the first 6 months which seems
to agree with our finding.
New onset depression in people with newly diagnosed TB could
be the result of the active inflammatory process directly leading to
depression in susceptible individuals (Herbert and Cohen, 1993;
Raison et al., 2006; Dantzer et al., 2008), stress of encountering
an infectious diseases with risk to others, decreased functioning
from illness and psychological loss (Pachi et al., 2013), and, taking
multiple drugs with warnings that failure to adhere will have dire
consequences. The first 2 months from the start of anti-TB medi-
cations is also a period when most medication side effects occur
(Yee et al., 2003; Gulbay et al., 2006). With time, people with TB
are more likely to develop better coping strategies (Olley et al.,
2006). The relative reduction in the incidence rate after 2 months
in the presence of continued isoniazid and discontinued etham-
butol doses may be a point of interest for future investigation on
the relationship of these medications with depression.
Our finding that female sex predicts incidence of depression
agrees with previous studies in various populations (Kessler
et al., 1993; Buchtemann et al., 2012; Huang et al., 2012; Nefs
et al., 2012; Elenga et al., 2014; Lunghi et al., 2016). Likewise,
the protective effect of social support was in agreement with
what was observed in diabetes cohort (Lunghi et al., 2016). This
finding can be a supportive evidence to assert the notion that
enhancing the support system of TB patients can reduce depres-
sion. The higher incidence of depression in people with pulmon-
ary TB than for extra pulmonary TB may be related to the higher
communicability of pulmonary TB which puts all close contacts,
mainly household members, at a high risk of developing TB, and
this undue cognitive stress could lead to depression; but biological
mechanisms should also be investigated.
Limitations
We used a screening tool to assess depression. We might have
reported undiagnosed prevalent cases as incident as the health
Fig. 2. Flow chart of follow up of participants who
did not have baseline probable depression.
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system may not be strong enough to diagnose depression in the
context of TB where there is overlap between TB and depression
symptoms. For example, none of the participants who scored
above the cut point of PHQ-9 and none of the participants who
we referred to health professionals because they endorsed the ‘sui-
cide item of PHQ-9’ were diagnosed to have depression by the
trained primary care workers.
Undiagnosed physical illnesses, poverty, and loss to follow up
might have confounded our findings. Because the study was con-
ducted in a setting where the health system is not as such strong,
our participants could have had undiagnosed comorbid physical
illnesses that might have increased incidence of depression.
Another potentially confounding factor is poverty which may
not have been fully captured by our socio-demographic variables.
Lastly, we had no information on whether participants transferred
out of the study area differed significantly from others in terms of
developing depression. In addition to that our conclusions cannot
be extended to TB patients who are hospitalized, are being
re-treated, or have multidrug-resistant disease.
Our sampling technique was a family of non-probability
sampling. Nevertheless, as the consecutive sample met criteria
for robustness (multiple sites, long data collection period, all
eligible participants approached to participate) (Mathieson,
2014) it should be reasonably representative of adults
with newly diagnosed TB in the outpatient department.
Theoretically, information bias was a possibility due to a change
in the capacity of the assessors as they become more familiar
with more practice over time. There are no statistical methods
to check this bias and its direction cannot be determined in
this specific situation. However, the rigorous training given to
Table 3. Predictors of incidence of depression in TB patients (n = 279)
Variables
2 months
Rate (95% CI)/adjustedβ (95% CI)
6 months
Rate (95% CI)/adjustedβ (95% CI)
Incidence rate per 1000 person-months 73.6 (42.8–104.3) 24.2 (14.9–33.5)
Sex
Male 1 1
Female 0.40 (0.16–0.63)** 0.22 (0.16–0.27)***
Agea 0.01 (−0.01–0.02) 0.001(−0.001–0.02)
Marital status
Single 1 1
Married 0.37 (0.34–0.40)*** 0.04 (−0.001–0.08)
Widowed or divorced 0.56 (−0.27–1.38) 0.12 (−0.84–0.08)
Level of education
No formal education 1 1
Primary education 1.10 (−0.15 to 2.34) 0.71 (−0.63 to 2.06)
⩾ Secondary −1.10 (−3.99 to 1.79) −1.59 (−4.85 to 1.66)
Religion
Christian 1 1
Muslim 0.23 (−0.39 to 0.85) 0.15 (−0.86 to 1.17)
Residence
Urban 1 1
Rural 0.17 (−0.06 to 0.40) 0.08 (−0.27 to 0.43)
Annual household incomea 0.001 (−0.001 to 0.001) −0.001 (0.001–0.001)
Perceived social supporta −0.15 (−0.23 to −0.07)*** −0.14 (−0.24 to −0.03)**
TB related stigmaa 0.10 (−0.03 to 0.24) 0.09 (−0.03 to 0.21)
HIV status
Negative 1 1
Positive −0.69 (−3.62 to 2.23) −0.73 (−3.28 to 0.82)
Unknown −1.09 (−1.28 to −0.90) −0.01 (−0.33 to 0.32)
Type of TB
Pulmonary 0.23 (0.001–0.45)* 0.29 (0.18–0.40)***
Extra pulmonary 1 1
Adjusted β = regression coefficients;* = p < 0.05; ** = p < 0.01; **** = p < 0.001
Adjustment was done for all the variables in the table.
aThe variables were measured at the continuous level.
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field workers before starting data collection is expected to min-
imize this bias.
A potential concern regarding generalizability is homogeneity
of the TB treatment approach in other settings and the sustain-
ability of the current practice of TB treatment in future
(Partridge et al., 2015). TB is being treated according to the
DOTS approach introduced by the WHO in 1994 (Onozaki and
Raviglione, 2010) and this approach is being adhered in the global
strategy of ‘End-TB by 2030’ (World Health Organization, 2015).
It is therefore similar across low-income country settings and is
likely to be sustained in the coming years. In conclusion, the
observed findings would seem to be reasonably valid for the
study population as well as being generalizable to adults with
newly diagnosed TB in outpatient settings elsewhere in Ethiopia
as well as in similar settings in Sub Saharan Africa.
Conclusions
The high incidence rate of probable depression was found in peo-
ple with newly diagnosed TB and undergoing treatment. Most
incident cases occurred during the first 2 months and the inci-
dence rate relatively decreased with time during the continuation
phase of anti-TB treatment despite continued use of isoniazid.
The long term course of incident cases of depression, and for
how long incidence rate remains high in this population after
the TB is treated requires further study. TB care guidelines should
have mental health components.
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